b'<?xml version="1.0" encoding="utf-8"?>\n<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">\n<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">\n    \n    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />\n        <!-- AppResources meta begin -->\n        <script type="text/javascript">var ncbi_startTime = new Date();</script>\n        <!-- AppResources meta end -->\n        \n        <!-- TemplateResources meta begin -->\n        <meta name="paf_template" content="" />\n\n        <!-- TemplateResources meta end -->\n        \n        <!-- Logger begin -->\n        <meta name="ncbi_db" content="pmc" /><meta name="ncbi_pdid" content="article" /><meta name="ncbi_acc" content="" /><meta name="ncbi_domain" content="phenaturepg" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/articles/PMC1525181/" /><meta name="ncbi_app" content="pmc" />\n        <!-- Logger end -->\n        \n        <title>The synergistic effect of IFN-\xce\xb1 and IFN-\xce\xb3 against HSV-2 replication in Vero cells is not interfered by the plant antiviral 1-cinnamoyl-3, 11-dihydroxymeliacarpin</title>\n        \n        <!-- AppResources external_resources begin -->\n        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>\n\n        <!-- AppResources external_resources end -->\n        \n        <!-- Page meta begin -->\n        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1525181/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Virology Journal" /><meta name="citation_title" content="The synergistic effect of IFN-\xce\xb1 and IFN-\xce\xb3 against HSV-2 replication in Vero cells is not interfered by the plant antiviral 1-cinnamoyl-3, 11-dihydroxymeliacarpin" /><meta name="citation_authors" content="Erina Petrera, Celia E Coto" /><meta name="citation_date" content="2006" /><meta name="citation_volume" content="3" /><meta name="citation_doi" content="10.1186/1743-422X-3-45" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC1525181/?report=abstract" /><meta name="citation_pmid" content="16772029" /><meta name="DC.Title" content="The synergistic effect of IFN-\xce\xb1 and IFN-\xce\xb3 against HSV-2 replication in Vero cells is not interfered by the plant antiviral 1-cinnamoyl-3, 11-dihydroxymeliacarpin" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Nature Publishing Group" /><meta name="DC.Contributor" content="Erina Petrera" /><meta name="DC.Contributor" content="Celia E Coto" /><meta name="DC.Date" content="2006" /><meta name="DC.Identifier" content="10.1186/1743-422X-3-45" /><meta name="DC.Language" content="en" /><meta property="og:title" content="The synergistic effect of IFN-\xce\xb1 and IFN-\xce\xb3 against HSV-2 replication in Vero cells is not interfered by the plant antiviral 1-cinnamoyl-3, 11-dihydroxymeliacarpin" /><meta property="og:type" content="article" /><meta property="og:description" content="Recent studies have shown that gamma interferon (IFN-\xce\xb3) synergizes with IFN-\xce\xb1/\xce\xb2 to inhibit herpes simplex virus type 1 (HSV-1) replication in vitro. Since IFN response represents an early host defense event against viral infection ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1525181/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbi" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print" /><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:\'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/\'" /><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css" /><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-phenaturepg.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">\n        div.pmc_para_cit li.highlight,\n        div.pmc_para_cit li.highlight .one_line_source\n        { background: #E0E0E0; }\n        a.bibr.highlight { background: #E0E0E0; } \n      </style><meta name="cited_in_systematic_reviews" content="" /><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC1525181/epub/" /><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC1525181/pdf/12985_2006_Article_152.pdf" />\n\n        <!-- Page meta end -->\n    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="8A1B67CAE999B5B10000000008A208A1.m_8" />\n<meta name=\'referrer\' content=\'origin-when-cross-origin\'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print" /></head>\n    <body class="article">\n        <div class="grid">\n            <div class="col twelve_col nomargin shadow">\n                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->\n                <div class="sysmessages">\n                    <noscript>\n\t<p class="nojs">\n\t<strong>Warning:</strong>\n\tThe NCBI web site requires JavaScript to function. \n\t<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>\n\t</p>\n\t</noscript>\n                </div>\n                <!--/.sysmessage-->\n                <div class="wrap">\n                    <div class="page">\n                        <div class="top">\n                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main\n                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to\n                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>\n                            <div class="header">\n    <div class="res_logo">\n  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>\n  <div class="NLMLogo">\n    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>\n    <br />\n    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>\n  </div>\n</div>\n    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" class="last" data-ac_dict="pmc-search-autocomplete">PMC</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:\'pmc-search-autocomplete\',disableUrl:\'NcbiSearchBarAutoComplCtrl\'" autocomplete="off" data-sbconfig="ds:\'no\',pjs:\'no\',afs:\'yes\'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>\n                        <a href="/pmc/advanced/">Advanced</a>\n                    </li><li>\n                        <a href="/pmc/journals/">Journal list</a>\n                    </li><li class="help">\n                        <a target="_blank" href="/books/NBK3825/">Help</a>\n                    </li></ul></div>\n</div>\n\n                            \n                            \n                        <!--<component id="Page" label="headcontent"/>-->\n                            \n                        </div>\n                        <div class="content">\n                            <!-- site messages -->\n                            <div class="container">\n    <div id="maincontent" class="content eight_col col">\n        <div class="navlink-box">\n            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="article-entrez-filter"><a href="/pmc/?term=Nature%20Public%20Health%20Emergency%20Collection[filter]" class="navlink">Nature Public Health Emergency Collection</a></li><li class="accid">PMC1525181</li></ul>\n        </div>\n\n        <!-- Journal banner -->\n        <div class="pmc-page-banner whole_rhythm"><div class="banner-generic-logo-background inline_block"><div class="banner-journal-publisher-over-image"><div class="banner-journal-name bl-jtitle-phenaturepg">Virology Journal</div><div class="banner-publisher-name">Nature Publishing Group</div></div></div></div>\n        \n        <!--component id=\'MainPortlet\' label=\'search-reference\'/-->\n        \n        <!-- Book content -->\n        <div class="">\n            \n        \n            \n            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [\'h2\'], headingExclude: \':hidden\'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><div><span class="cit"><span id="pmcmata">Virol J</span>. 2006; 3: 45. </span></div><div><span class="fm-vol-iss-date">Published online 2006 Jun 13. </span>  <span class="doi">doi:\xc2\xa0<a href="//dx.doi.org/10.1186%2F1743-422X-3-45" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1186/1743-422X-3-45</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC1525181</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/16772029">16772029</a></div></div></div></div><h1 class="content-title">The synergistic effect of IFN-&#x003b1; and IFN-&#x003b3; against HSV-2 replication in Vero cells is not interfered by the plant antiviral 1-cinnamoyl-3, 11-dihydroxymeliacarpin</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Petrera%20E%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16772029" class="affpopup" co-rid="_co_idm140416951525936" co-class="co-affbox">Erina Petrera</a><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup><sup></sup> and  <a href="/pubmed/?term=Coto%20CE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16772029" class="affpopup" co-rid="_co_idm140416962386720" co-class="co-affbox">Celia E Coto</a><sup></sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140416951525936"><h3 class="no_margin">Erina Petrera</h3><p>Laboratory of Virology, Department of Biochemistry, School of Science, University of Buenos Aires, Buenos Aires, Argentina </p><div>Find articles by <a href="/pubmed/?term=Petrera%20E%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16772029">Erina Petrera</a></div></div><div id="_co_idm140416962386720"><h3 class="no_margin">Celia E Coto</h3><p>Laboratory of Virology, Department of Biochemistry, School of Science, University of Buenos Aires, Buenos Aires, Argentina </p><div>Find articles by <a href="/pubmed/?term=Coto%20CE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=16772029">Celia E Coto</a></div></div></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm140416959295824_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140416959295824_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm140416959295824_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm140416959295824_ai" style="display:none"><div class="fm-affl" lang="en" id="Aff1">Laboratory of Virology, Department of Biochemistry, School of Science, University of Buenos Aires, Buenos Aires, Argentina </div><div><span class="fm-affl">Erina Petrera, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ra.abu.necf.bq@arertepe" class="oemail">ra.abu.necf.bq@arertepe</a></span>.</div><div><a href="#idm140416959295824aff-info">Contributor Information</a>.</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div></div><div class="fm-article-notes fm-panel hide half_rhythm" id="idm140416959295824_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2006 Mar 6; Accepted 2006 Jun 13.</div></div><div class="permissions fm-panel half_rhythm hide" id="idm140416959295824_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> &#x000a9; Petrera and Coto; licensee BioMed Central Ltd. 2006</div><div class="license half_rhythm">This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href="http://creativecommons.org/licenses/by/2.0" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">http://creativecommons.org/licenses/by/2.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>This article has been <a href="/pmc/articles/PMC1525181/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="Abs1" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="Abs1title">Abstract</h2><!--article-meta--><div><div id="__sec1" class="sec sec-first"><h3 id="__sec1title">Background</h3><p id="__p1" class="p p-first-last">Recent studies have shown that gamma interferon (IFN-&#x003b3;) synergizes with IFN-&#x003b1;/&#x003b2; to inhibit herpes simplex virus type 1 (HSV-1) replication <em>in vitro</em>. Since IFN response represents an early host defense event against viral infection and the fact that treatment with meliacine, a plant antiviral, ameliorate the severity of the herpetic infection in female mice infected intravaginally with HSV-2, we wanted to investigate whether the administration of meliacine to HSV-2 infected mice could altered the homoestasis of IFNs host response. For this purpose we studied the effect of the compound 1-cinnamoyl-3,11-dihydroxymeliacarpin (CDM), which is the responsible for meliacine antiviral action, on the HSV-2 inhibition exerted by IFN &#x003b1;, IFN-&#x003b3; or their combination.</p></div><div id="__sec2" class="sec"><h3 id="__sec2title">Results</h3><p id="__p2" class="p p-first-last">We have found that like HSV-1, IFN-&#x003b3; synergizes with IFN-&#x003b1; to inhibit HSV-2 replication in Vero cells. While treatment with IFN-&#x003b1; or IFN-&#x003b3; alone has weak antiviral action, HSV-2 plaque formation, viral replication and the onset of viral CPE in Vero cells are synergistically inhibited by interferon combination. In addition, CDM treatment contributes to protect cells from virus cytopathic effect and causes a strong inhibition of HSV-2 titer. Moreover, the presence of CDM for 2 h before IFN induction, during the 16 h induction period, only for 24 h after infection or during the complete IFN treatment period, reduces virus yields in an additive way without affecting IFN antiviral action.</p></div><div id="__sec3" class="sec"><h3 id="__sec3title">Conclusion</h3><p id="__p3" class="p p-first-last">The results reported here indicated that the presence of CDM did not alter the antiviral activity of IFN-&#x003b1;, IFN-&#x003b3; or the synergism exerted by their combination. As a result we can envision that the administration of CDM <em>in vivo</em> could not affect the biological activity of IFNs, which are so important mediators of the innate resistance to HSV-2 infection.</p></div><div id="__sec4" class="sec sec-last"><h3 id="__sec4title">Electronic supplementary material</h3><p id="__p4" class="p p-first-last">The online version of this article (doi:10.1186/1743-422X-3-45) contains supplementary material, which is available to authorized users.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">Vero Cell, Antiviral Effect, Plaque Reduction Assay, Melia Azedarach, Virus Harvest</span></div></div><div id="Sec1" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec1title">Background</h2><p id="__p5" class="p p-first">Herpes simplex virus type 2 (HSV-2) is a sexually transmitted pathogen that infects both the oral and genital mucosa of humans and is a significant cause of morbidity worldwide. A mouse vaginal model of HSV-2 infection has been developed by several investigators [<a href="#CR1" rid="CR1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739919">1</a>&#x02013;<a href="#CR4" rid="CR4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739922">4</a>]. Although the degree of pathogenicity of the virus for mice is dependent on the virus strain used, in general, experimental infection by vaginal route (i.v) results in neurological disease, which is preceded by easily recognizable symptoms due to inflammation followed by rear leg paralysis and death. This mouse model provides a useful tool to test the effect of antivirals against HSV-2 infection.</p><p id="__p6">Many studies have been performed in our laboratory with an antiviral compound isolated from the leaves of <em>Melia azedarach</em> L. named meliacine (MA). We have shown that meliacine strongly inhibited the replication of HSV-1 and HSV-2 in Vero cells [<a href="#CR5" rid="CR5" class=" bibr popnode">5</a>] and exhibits a synergistic antiviral activity when combined with acyclovir [<a href="#CR6" rid="CR6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739939">6</a>]. Studies performed by Alch&#x000e9; <em>et al</em> suggested that MA exerts the antiviral action on both synthesis of viral DNA and maturation and progress of HSV-1 on Vero cells [<a href="#CR7" rid="CR7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739944">7</a>]. <em>In vivo</em> studies have shown that meliacine prevents the development of HSV-1 stromal keratitis in mice [<a href="#CR8" rid="CR8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739924">8</a>, <a href="#CR9" rid="CR9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739917">9</a>]. Likewise, the severity of the herpetic infection in female mice infected intravaginally with HSV-2 was also ameliorated by MA treatment [<a href="#CR10" rid="CR10" class=" bibr popnode">10</a>]. On the other hand, besides its broad effect of antiviral action, meliacine acts as an immunomodulator in vitro agent inhibiting the phagocytosis of opsonized sheep erythrocytes and impairing the proliferation of spleen and lymph node T cells [<a href="#CR11" rid="CR11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739936">11</a>, <a href="#CR12" rid="CR12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739911">12</a>]. Moreover, meliacine is a weak inducer of tumor necrosis factor alpha (TNF-&#x003b1;) in murine macrophage cultures and causes a synergistic effect on the production of TNF-&#x003b1; induced by LPS [<a href="#CR13" rid="CR13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739928">13</a>]. Vaginal washes of female mice infected i.v. with HSV-2 and treated with meliacine contained an increased amount of TNF-&#x003b1; in comparison with infected non-treated animals [<a href="#CR10" rid="CR10" class=" bibr popnode">10</a>].</p><p id="__p7">IFN response represents an early host defense event, one that occurs prior to the onset of the immune response. In this context, macrophages play a central role in resistance of mice to primary infection with HSV-2, mainly, as a source of antiviral cytokines, TNF-&#x003b1;, IFN &#x003b1;/&#x003b2; and IL-12, which are produced rapidly after infection [<a href="#CR14" rid="CR14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739940">14</a>]. IFN-&#x003b3;, a strong activator of macrophages [<a href="#CR15" rid="CR15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739921">15</a>&#x02013;<a href="#CR17" rid="CR17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739931">17</a>] is produced both in the early stages of infection by natural killer cells and at later stages by activated T cells [<a href="#CR18" rid="CR18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739932">18</a>]. The innate immune response to viral infection depends on the integrity of this network of cytokines, which is tightly regulated [<a href="#CR19" rid="CR19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739951">19</a>]. This <em>in vivo</em> situation led us to query whether the administration of meliacine to HSV-2 infected mice could altered the homoestasis of IFNs host response either affecting the antiviral activity of IFN &#x003b1;/&#x003b2; or IFN-&#x003b3;, or their synergizing interaction [<a href="#CR20" rid="CR20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739916">20</a>, <a href="#CR21" rid="CR21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739945">21</a>]. To answer that question we conducted experiments following an indirect approach based on the observation that IFN-&#x003b3; synergizes with IFN &#x003b1;/&#x003b2; to inhibit HSV-1 replication in Vero cells [<a href="#CR20" rid="CR20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739915">20</a>]. To that end, Vero cells infected with HSV-2 were treated with IFN-&#x003b1;, IFN-&#x003b3; or a combination of both in the presence or absence of meliacine under different experimental conditions.</p><p id="__p8" class="p p-last">To perform these experiments instead of meliacine, we worked with the compound 1-cinnamoyl-3,11-dihydroxymeliacarpin (CDM) which is the molecule responsible for the broad spectrum of meliacine antiviral action [<a href="#CR22" rid="CR22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845249180">22</a>]. In summary, here we analyzed: <em>i)</em> the susceptibility of HSV-2 to IFN-&#x003b1;, IFN-&#x003b3; or the combination of both in Vero cells since no published data is available with this herpesvirus; <em>ii)</em> the effect of CDM on interferons action.</p></div><div id="Sec2" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec2title">Results</h2><div id="Sec3" class="sec sec-first"><h3 id="Sec3title">Antiviral effect of IFN-&#x003b1;, IFN-&#x003b3; and IFNs combination on HSV-2 plaque formation</h3><p id="__p9" class="p p-first">Since there is no published data on the effect of IFNs on HSV-2 infection in Vero cells the capacity of human IFN-&#x003b1; and/or IFN-&#x003b3; to inhibit the replication of HSV-2 strains MS and G was initially performed in a plaque reduction assay. The concentration of IFN-&#x003b1; and IFN-&#x003b3; used in the present experiment were those previously tested against HSV-1 (KOS strain) [<a href="#CR20" rid="CR20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739946">20</a>]. Vero cells were pretreated for 16 hours with 100 IU/ml of IFNs separately or in combination and infected with HSV-2 (MS or G strain) at the MOI of 1 PFU per cell. HSV-1 (KOS and F strains) were also tested using the same MOI and served as controls. The efficiency of HSV-1 strains KOS and F plaque formation was quite modestly reduced by the presence of IFN-&#x003b1; or IFN-&#x003b3; alone. Whereas, the combination of IFN-&#x003b1; and IFN-&#x003b3; acted synergistically as previously reported for HSV-1 [<a href="#CR20" rid="CR20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739949">20</a>, <a href="#CR23" rid="CR23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739942">23</a>].</p><p id="__p10">Simultaneous treatment of Vero cells with both IFN-&#x003b1; and IFN-&#x003b3; reduced HSV-2 plaque formation 3.8 fold for MS strain and 8.6 fold for G strain in comparison with the effect of each IFN alone (Table <a href="/pmc/articles/PMC1525181/table/Tab1/" target="table" class="fig-table-link figpopup" rid-figpopup="Tab1" rid-ob="ob-Tab1" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">(Table1).</span></span><span>1</span></a>). Likewise HSV-1, the level of inhibition achieved with IFN-&#x003b1; and IFN-&#x003b3; combination treatment was not a consequence of doubling the amount of IFN per culture. As seen in Table <a href="/pmc/articles/PMC1525181/table/Tab1/" target="table" class="fig-table-link figpopup" rid-figpopup="Tab1" rid-ob="ob-Tab1" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">Table1,</span></span><span>1</span></a>, increasing the concentration of each IFN to 200 IU/ml did not augment the inhibitory effect.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="Tab1"><h3>Table 1</h3><!--caption a7--><div class="caption"><p id="__p11">Effect of IFN-&#x003b1; and IFN-&#x003b3; on HSV-2 and HSV-1 plaque formation on Vero cells.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140416952154160" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1"></th><th align="left" rowspan="1" colspan="1">Treatment (IU/ml)<sup>a</sup></th><th align="center" rowspan="1" colspan="1">Mean no. of plaques<sup>b</sup> &#x000b1; SEM</th><th align="center" rowspan="1" colspan="1">Fold reduction<sup>c</sup></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">HSV-2 MS</td><td align="left" rowspan="1" colspan="1">Vehicle</td><td align="center" rowspan="1" colspan="1">137 &#x000b1; 8.3</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">IFN-&#x003b1; (100)</td><td align="center" rowspan="1" colspan="1">82.5 &#x000b1; 6.4</td><td align="center" rowspan="1" colspan="1">1.7</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">IFN-&#x003b3; (100)</td><td align="center" rowspan="1" colspan="1">86 &#x000b1; 6.6</td><td align="center" rowspan="1" colspan="1">1.6</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">IFN-&#x003b1; (100)+IFN-&#x003b3; (100)</td><td align="center" rowspan="1" colspan="1">36.5 &#x000b1; 4.3</td><td align="center" rowspan="1" colspan="1">\n<strong>3.8</strong>\n</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">IFN-&#x003b1; (200)</td><td align="center" rowspan="1" colspan="1">68 &#x000b1; 5.8</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">IFN-&#x003b3; (200)</td><td align="center" rowspan="1" colspan="1">72 &#x000b1; 6</td><td align="center" rowspan="1" colspan="1">1.9</td></tr><tr><td align="left" rowspan="1" colspan="1">HSV-2 G</td><td align="left" rowspan="1" colspan="1">Vehicle</td><td align="center" rowspan="1" colspan="1">98.5 &#x000b1; 7</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">IFN-&#x003b1; (100)</td><td align="center" rowspan="1" colspan="1">81 &#x000b1; 6.4</td><td align="center" rowspan="1" colspan="1">1.2</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">IFN-&#x003b3; (100)</td><td align="center" rowspan="1" colspan="1">98 &#x000b1; 7</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">IFN-&#x003b1; (100) + IFN-&#x003b3; (100)</td><td align="center" rowspan="1" colspan="1">11.5 &#x000b1; 2.4</td><td align="center" rowspan="1" colspan="1">\n<strong>8.6</strong>\n</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">IFN-&#x003b1; (200)</td><td align="center" rowspan="1" colspan="1">52 &#x000b1; 5.1</td><td align="center" rowspan="1" colspan="1">1.9</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">IFN-&#x003b3; (200)</td><td align="center" rowspan="1" colspan="1">35 &#x000b1; 4.2</td><td align="center" rowspan="1" colspan="1">2.8</td></tr><tr><td align="left" rowspan="1" colspan="1">HSV-1 KOS</td><td align="left" rowspan="1" colspan="1">Vehicle</td><td align="center" rowspan="1" colspan="1">133 &#x000b1; 8.2</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">IFN-&#x003b1; (100)</td><td align="center" rowspan="1" colspan="1">68.5 &#x000b1; 5.9</td><td align="center" rowspan="1" colspan="1">1.9</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">IFN-&#x003b3; (100)</td><td align="center" rowspan="1" colspan="1">74.5 &#x000b1; 6.1</td><td align="center" rowspan="1" colspan="1">1.8</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">IFN-&#x003b1; (100) + IFN-&#x003b3; (100)</td><td align="center" rowspan="1" colspan="1">4 &#x000b1; 1.4</td><td align="center" rowspan="1" colspan="1">\n<strong>33</strong>\n</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">IFN-&#x003b1; (200)</td><td align="center" rowspan="1" colspan="1">54.5 &#x000b1; 5.2</td><td align="center" rowspan="1" colspan="1">2.4</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">IFN-&#x003b3; (200)</td><td align="center" rowspan="1" colspan="1">84.5 &#x000b1; 6.5</td><td align="center" rowspan="1" colspan="1">1.6</td></tr><tr><td align="left" rowspan="1" colspan="1">HSV-1 F</td><td align="left" rowspan="1" colspan="1">Vehicle</td><td align="center" rowspan="1" colspan="1">100 &#x000b1; 7.1</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">IFN-&#x003b1; (100)</td><td align="center" rowspan="1" colspan="1">82.5 &#x000b1; 6.4</td><td align="center" rowspan="1" colspan="1">1.2</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">IFN-&#x003b3; (100)</td><td align="center" rowspan="1" colspan="1">84.5 &#x000b1; 6.5</td><td align="center" rowspan="1" colspan="1">1.2</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">IFN-&#x003b1; (100) + IFN-&#x003b3; (100)</td><td align="center" rowspan="1" colspan="1">19 &#x000b1; 3.1</td><td align="center" rowspan="1" colspan="1">\n<strong>5.3</strong>\n</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">IFN-&#x003b1; (200)</td><td align="center" rowspan="1" colspan="1">51.5 &#x000b1; 5.1</td><td align="center" rowspan="1" colspan="1">1.9</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">IFN-&#x003b3; (200)</td><td align="center" rowspan="1" colspan="1">53 &#x000b1; 5.1</td><td align="center" rowspan="1" colspan="1">1.9</td></tr></tbody></table></div><div id="largeobj_idm140416952154160" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC1525181/table/Tab1/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><p id="__p12"><sup>a</sup>Vero cells were treated continuously with IFN-&#x003b1;, IFN-&#x003b3; or combinations of these cytokines from 16 h before infection until the end of the experiment.</p><p id="__p13"><sup>b</sup> Average number of plaques per well of Vero cells inoculated with 200 PFU of HSV-1 KOS and F and HSV-2 MS and G. Values represent (mean &#x000b1; SEM) from three independent experiments.</p><p id="__p14"><sup>c</sup> Fold-reduction in each group was calculated as follows: number of plaques in vehicle/number of plaques in treatments. Values represent mean from three independent experiments. P &#x0003c; 0.05, as determined by one-way ANOVA and Turkey\'s post hoc <em>t</em> test comparison of this treatment to vehicle.</p></div></div><p id="__p15" class="p p-last">These results indicate that HSV-2 replication in Vero cells, as other members of the herpes virus family like HSV-1 [<a href="#CR20" rid="CR20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739947">20</a>], VZV [<a href="#CR24" rid="CR24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739938">24</a>] and CMV [<a href="#CR25" rid="CR25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739909">25</a>] shows an increased susceptibility to IFN combination with respect to each IFN alone.</p></div><div id="Sec4" class="sec"><h3 id="Sec4title">Effect of IFN-&#x003b1; and IFN-&#x003b3; on HSV-2 replication</h3><p id="__p16" class="p p-first-last">To further characterize the inhibitory effect of IFN-&#x003b1; and IFN-&#x003b3; treatment on HSV-2 replication, three days viral growth assay were performed. Vero cells were pretreated for 16 h with 100 IU/ml of IFNs separately or in combination. Then, cells were infected with HSV-2 (MS or G strain) at the MOI of 1 PFU per cell and culture supernatants were harvested at 24, 48 and 72 h p.i. and titered for infectious virus. For control purpose HSV-1 strains KOS and F similarly treated were included. In accordance with the results presented in Table <a href="/pmc/articles/PMC1525181/table/Tab1/" target="table" class="fig-table-link figpopup" rid-figpopup="Tab1" rid-ob="ob-Tab1" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">Table1,</span></span><span>1</span></a>, we observed a greater inhibitory effect on HSV-2 replication when Vero cultures were treated with IFNs combination than IFN-&#x003b1; or IFN-&#x003b3; alone, despite that each interferon showed a greater antiviral activity than in plaque reduction assay (Figure <a href="/pmc/articles/PMC1525181/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure1).</span></span><span>1</span></a>). In cultures treated with 100 IU/ml of IFN-&#x003b1; or IFN-&#x003b3;, MS and G replication was 8-fold and 100-fold reduced respectively (p &#x0003c; 0.001) at 24 h p.i. (Figure <a href="/pmc/articles/PMC1525181/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure1a</span></span><span>1a</span></a> and <a href="/pmc/articles/PMC1525181/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -1.5em;">and1b).</span></span><span>1b</span></a>). At 48 and 72 h p.i. viral titers in IFN-&#x003b1; or IFN-&#x003b3;-treated cultures approached levels of those detected in vehicle-treated groups. However, relative to vehicle control cultures, viral titers recovered at 48 and 72 h from cultures treated with IFN-&#x003b1; or IFN-&#x003b3; were reduced by 2-fold in MS-infected cultures and 2-and 3-fold in G infected cultures respectively (Figure <a href="/pmc/articles/PMC1525181/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure1e</span></span><span>1e</span></a> and <a href="/pmc/articles/PMC1525181/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -1.5em;">and1f).</span></span><span>1f</span></a>). In HSV-2 infected cultures treated with combination of IFN-&#x003b1; and IFN-&#x003b3; the inhibitory effect was different between strains. Titers of HSV-2 MS were reduced 100-fold approximately relative to vehicle treated Vero cells at all time point tested. In the case of HSV-2 G, IFN combination virus titers were reduced 10.000-fold in comparison to control cultures at 24 h p.i. At 48 and 72 h p.i. the antiviral activity decreased, however virus replication was still 2000-fold inhibited. These results indicate that the combination of IFN-&#x003b1; and IFN-&#x003b3; synergizes the antiviral effect against HSV-2 in a similar mode to previously reported for HSV-1 (Figure <a href="/pmc/articles/PMC1525181/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure1c,</span></span><span>1c</span></a>, <a href="/pmc/articles/PMC1525181/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -0.5em;">,1d,</span></span><span>1d</span></a>, <a href="/pmc/articles/PMC1525181/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -0.5em;">,1g</span></span><span>1g</span></a> and <a href="/pmc/articles/PMC1525181/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -1.5em;">and1h)</span></span><span>1h</span></a>) [<a href="#CR23" rid="CR23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739926">23</a>, <a href="#CR25" rid="CR25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739941">25</a>].</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig1" co-legend-rid="lgnd_Fig1"><a href="/pmc/articles/PMC1525181/figure/Fig1/" target="figure" rid-figpopup="Fig1" rid-ob="ob-Fig1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140416957509472" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2006_Article_152_Fig1_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2006_Article_152_Fig1_HTML.jpg" src="/pmc/articles/PMC1525181/bin/12985_2006_Article_152_Fig1_HTML.jpg" /></div><div id="largeobj_idm140416957509472" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC1525181/figure/Fig1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig1"><div><a class="figpopup" href="/pmc/articles/PMC1525181/figure/Fig1/" target="figure" rid-figpopup="Fig1" rid-ob="ob-Fig1">Figure 1</a></div><!--caption a7--><div class="caption"><p id="__p17">Effect of IFN-&#x003b1; and IFN-&#x003b3; on HSV replication. Vero cells were treated with (&#x025a0;) vehicle or 100 IU/ml each of (&#x025cf;) IFN-&#x003b1;, (&#x025b2;) IFN-&#x003b3; or (&#x025bc;) IFN-&#x003b1; and IFN-&#x003b3; 16 h before infection with HSV-2 strain (a, e) MS, HSV-2 strain (b, f) G, HSV-1 strain (c, g) KOS or HSV-1 strain (d, h) F at a MOI of 1 PFU per cell. Supernatants were harvested on the indicated days p.i. and viral titers were determined by plaque assay as described in Material and Methods. (e-h) Average fold inhibition in viral replication observed in cells treated 100 IU/ml each of (<span id="Equ1"><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2006_Article_152_Equa_HTML.gif" src="/pmc/articles/PMC1525181/bin/12985_2006_Article_152_Equa_HTML.gif" class="equation" /></span>)IFN-&#x003b1;, (&#x025a1;) IFN-&#x003b3; or (&#x025a0;) IFN-&#x003b1; and IFN-&#x003b3; was calculated as (average viral titers in vehicle-treated/average viral titers in IFN-treated). One-way ANOVA followed by Tukey\'s post hoc <em>t</em> test confirmed that the differences were significant (p &#x0003c; 0.001).</p></div></div></div></div><div id="Sec5" class="sec"><h3 id="Sec5title">Treatment with IFN combination protects HSV-2 infected cells from viral cytopathic effect (CPE)</h3><p id="__p18" class="p p-first">Due to the long time that IFNs were in contact with cells in the experiments just described we performed new ones in order to discard any cytotoxicity due to the cytokines that could affect the results observed. For that purpose cultures of Vero cells were treated for 16 h with IFN-&#x003b1;, IFN-&#x003b3; or the combination of both. After that time, monolayers were infected with 1 PFU per cell of HSV-2 MS strain and fresh medium containing or not IFN was added after 1 h virus adsorption and remained up to the end of the experiment. Cell morphology was observed by light microscope and the number of viable cells at 0, 12, 24, 36 and 48 h p.i. was determined by MTT colorimetric assay. In comparison with vehicle treated uninfected cells, IFN treatment did not affect cell morphology or proliferation. (Figure <a href="/pmc/articles/PMC1525181/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure2a).</span></span><span>2a</span></a>). Infection with HSV-2 MS strain destroyed 87.5% of vehicle-treated cells by 48 h p.i. (Figure <a href="/pmc/articles/PMC1525181/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure2b).</span></span><span>2b</span></a>). Treatment with IFN-&#x003b1; or IFN-&#x003b3; delayed the onset of CPE in MS-infected cultures and increased the fraction of viable cells recovered between 24 and 36 h p.i. (Figure <a href="/pmc/articles/PMC1525181/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure2b).</span></span><span>2b</span></a>). However, at 48 h p.i. the cultures appeared like vehicle treated cells. By contrast, a combination of IFN-&#x003b1; and IFN-&#x003b3; provided the greatest protection, 75% of MS-infected cells remained viable at 48 h p.i. (Figure <a href="/pmc/articles/PMC1525181/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure2b</span></span><span>2b</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig2" co-legend-rid="lgnd_Fig2"><a href="/pmc/articles/PMC1525181/figure/Fig2/" target="figure" rid-figpopup="Fig2" rid-ob="ob-Fig2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140416956989536" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2006_Article_152_Fig2_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2006_Article_152_Fig2_HTML.jpg" src="/pmc/articles/PMC1525181/bin/12985_2006_Article_152_Fig2_HTML.jpg" /></div><div id="largeobj_idm140416956989536" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC1525181/figure/Fig2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig2"><div><a class="figpopup" href="/pmc/articles/PMC1525181/figure/Fig2/" target="figure" rid-figpopup="Fig2" rid-ob="ob-Fig2">Figure 2</a></div><!--caption a7--><div class="caption"><p id="__p19">Treatment with IFN protects HSV-2 infected cells from viral cytopathic effect. (a) Uninfected cells per culture that remained viable at different times after treatment with (&#x025a0;) vehicle, (&#x025cf;) 100 IU/ml IFN-&#x003b1;, (&#x025b2;) 100 IU/ml IFN-&#x003b3;, (<span id="Equ2"><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2006_Article_152_Equb_HTML.gif" src="/pmc/articles/PMC1525181/bin/12985_2006_Article_152_Equb_HTML.gif" class="equation" /></span>) 100 IU/ml each of IFN-&#x003b1; and IFN-&#x003b3;, (&#x025bc;) CDM, (&#x025c6;) CDM + IFN-&#x003b1;, (+) CDM + IFN-&#x003b3; and (<span id="IEq1"><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2006_Article_152_IEq1_HTML.gif" src="/pmc/articles/PMC1525181/bin/12985_2006_Article_152_IEq1_HTML.gif" class="equation" /></span>) CDM + IFN-&#x003b1; and IFN-&#x003b3;. (b) Number of MS-infected cells that remained viable at times after inoculation in the presence of (&#x025a0;) vehicle, (&#x025cf;) 100 IU/ml IFN-&#x003b1;, (&#x025b2;) 100 IU/ml IFN-&#x003b3; or (&#x025bc;) 100 IU/ml each of IFN-&#x003b1; and IFN-&#x003b3;. (c) Number of MS-infected cells that remained viable at times after inoculation in the presence of (&#x025a0;) CDM, (&#x025cf;) CDM + 100 IU/ml IFN-&#x003b1;, (&#x025b2;) CDM + 100 IU/ml IFN-&#x003b3; or (&#x025bc;) CDM + 100 IU/ml each of IFN-&#x003b1; and IFN-&#x003b3;.). One-way ANOVA followed by Tukey\'s post hoc <em>t</em> test confirmed that the differences were significant (p &#x0003c; 0.001).</p></div></div></div><p id="__p20" class="p p-last">The results of these experiments supported the previous findings (Table <a href="/pmc/articles/PMC1525181/table/Tab1/" target="table" class="fig-table-link figpopup" rid-figpopup="Tab1" rid-ob="ob-Tab1" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">(Table1</span></span><span>1</span></a> and Figure <a href="/pmc/articles/PMC1525181/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure1)</span></span><span>1</span></a>) that combination of IFN-&#x003b1; and IFN-&#x003b3; inhibited HSV-2 replication in Vero cells in a synergistic manner.</p></div><div id="Sec6" class="sec sec-last"><h3 id="Sec6title">Effect of IFN-&#x003b1;, IFN-&#x003b3; and IFN combination on HSV-2 replication in the presence of CDM</h3><p id="__p21" class="p p-first">In order to investigate whether or not CDM could interact with cytokines antiviral effect in Vero cells we performed several experiments. First, we tested the effect of CDM on cell CPE protection provided by IFN-&#x003b1;, IFN-&#x003b3; or the combination of both. For this purpose an experiment similar to that described in Figure <a href="/pmc/articles/PMC1525181/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure2b</span></span><span>2b</span></a> was performed but in the presence of CDM (50 &#x003bc;g/ml). The number of surviving cells was determined at 12, 24, 36 and 48 h p.i. (Figure <a href="/pmc/articles/PMC1525181/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure2c).</span></span><span>2c</span></a>). A comparison of Figure <a href="/pmc/articles/PMC1525181/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure2b</span></span><span>2b</span></a> and <a href="/pmc/articles/PMC1525181/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -1.5em;">and2c</span></span><span>2c</span></a> shows that in the presence of CDM alone Vero cells were highly protected from HSV-2 cytopathicity, since 60% of infected cells remained viable. When CDM was combined with IFN-&#x003b1; or IFN-&#x003b3;, the number of protected cells increased with respect to the effect of each interferon alone suggesting that the protection observed is due to CDM effect. Interestingly, when cells were treated with CDM plus IFN combination there seems to be an additive antiviral effect, a phenomenon that was confirmed by next experiments.</p><p id="__p22">We also tested if the presence of CDM under different experimental conditions could affect the antiviral action of IFNs on HSV-2 MS replication. Virus yields at 24 h p.i. were determined in Vero cells treated with CDM as follows: <em>i</em>) for 2 h prior to interferon induction and then removed, <em>ii</em>) added simultaneously with IFN and remained only for 16 h before infection, <em>iii</em>) added after virus infection and remained to virus harvest, <em>iiii</em>) added with IFN 16 h before infection, re-added after infection and remained to virus harvest. The results obtained following protocol <em>i</em>) are depicted in Figure <a href="/pmc/articles/PMC1525181/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure3a.</span></span><span>3a</span></a>. The antiviral effect due to interferon alone or in combination is 2-fold increased in cells pretreated with CDM, as an indication that CDM treatment did not interfere with the antiviral activity displayed by IFN alone or in combination. On the contrary, we can speculate that the antiviral effect of CDM alone contributed in an additive manner to the overall antiviral activity. When CDM was present during the 16 h IFN antiviral induction period, the interpretation of the results are rather complicated because of the antiviral effect of CDM <em>per se</em> which reduced HSV-2 replication by 20-fold (Figure <a href="/pmc/articles/PMC1525181/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure3b).</span></span><span>3b</span></a>). Likewise, in the experiments described in Figure <a href="/pmc/articles/PMC1525181/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure3a,</span></span><span>3a</span></a>, there is an additive effect of CDM when cells were treated with both IFN-&#x003b1; or IFN-&#x003b3; or their combination (Figure <a href="/pmc/articles/PMC1525181/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure3b).</span></span><span>3b</span></a>). When CDM was added after virus infection and remained until 24 h p.i. or it was also present during the induction period, the antiviral effect of the compound was so high (100-fold and 20.000-fold reduction virus yield respectively) that masked its interaction with IFNs (Figure <a href="/pmc/articles/PMC1525181/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure3c</span></span><span>3c</span></a> and <a href="/pmc/articles/PMC1525181/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -1.5em;">and3d).</span></span><span>3d</span></a>). For that reason, we repeated the experiment shown in Figure <a href="/pmc/articles/PMC1525181/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure3c</span></span><span>3c</span></a> with lower concentrations of CDM. Virus yields at 24 h p.i. in cultures treated with 6.12, 12.25, 25 and 50 &#x003bc;g/ml of CDM, or CDM plus 100 IU/ml of IFN-&#x003b1; or CDM plus 100 IU/ml of IFN-&#x003b3; were determined. As can be seen in Figure <a href="/pmc/articles/PMC1525181/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure4,</span></span><span>4</span></a>, CDM alone inhibited virus replication in a dose dependent manner. The combination of each IFN with CDM increased in 1 log the antiviral effect but without altering the kinetics of the inhibition observed.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig3" co-legend-rid="lgnd_Fig3"><a href="/pmc/articles/PMC1525181/figure/Fig3/" target="figure" rid-figpopup="Fig3" rid-ob="ob-Fig3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140416956937392" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2006_Article_152_Fig3_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2006_Article_152_Fig3_HTML.jpg" src="/pmc/articles/PMC1525181/bin/12985_2006_Article_152_Fig3_HTML.jpg" /></div><div id="largeobj_idm140416956937392" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC1525181/figure/Fig3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig3"><div><a class="figpopup" href="/pmc/articles/PMC1525181/figure/Fig3/" target="figure" rid-figpopup="Fig3" rid-ob="ob-Fig3">Figure 3</a></div><!--caption a7--><div class="caption"><p id="__p23">Effect of CDM on the antiviral action exerted by IFNs. Vero cells were treated with 100 IU/ml of IFN-&#x003b1;, 100 IU/ml IFN-&#x003b3; or a combination of both for 16 h before infection with HSV-2 MS. After virus adsorption cells were re-fed with fresh cytokines which remained until 24 h p.i.. Different CDM treatments were performed: (a) Cells were treated with CDM 2h prior to interferon induction and then removed; (b) CDM was added simultaneously with IFN and remained only for 16 h before infection; (c) CDM was added after virus infection and remained until virus harvest; (d) CDM was added with IFN 16 h before infection, re-added after infection and remained to virus harvest. Average fold inhibition was calculated as (average viral titers in vehicle-treated/average viral titers in IFN-treated).</p></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig4" co-legend-rid="lgnd_Fig4"><a href="/pmc/articles/PMC1525181/figure/Fig4/" target="figure" rid-figpopup="Fig4" rid-ob="ob-Fig4"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140416955304432" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2006_Article_152_Fig4_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 12985_2006_Article_152_Fig4_HTML.jpg" src="/pmc/articles/PMC1525181/bin/12985_2006_Article_152_Fig4_HTML.jpg" /></div><div id="largeobj_idm140416955304432" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC1525181/figure/Fig4/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig4"><div><a class="figpopup" href="/pmc/articles/PMC1525181/figure/Fig4/" target="figure" rid-figpopup="Fig4" rid-ob="ob-Fig4">Figure 4</a></div><!--caption a7--><div class="caption"><p id="__p24">Additive effect of CDM and IFNs on HSV-2 inhibition. Several concentrations of CDM were added after HSV-2 MS infection in Vero cells treated 16 h before with vehicle, 100 IU/ml of IFN-&#x003b1; or 100 IU/ml of IFN-&#x003b3;. Fresh IFN was re-added after infection too. Virus yields at 24 h p.i. were determined by plaque reduction assay. (&#x025a0;) CDM alone, (&#x025cf;) CDM + 100 IU/ml of IFN-&#x003b1;; (&#x025b2;) CDM + 100 IU/ml of IFN-&#x003b3;.</p></div></div></div><p id="__p25" class="p p-last">All these results suggest that the presence of CDM did not interfere with the anti-HSV-2 inhibition of IFN-&#x003b1; or IFN-&#x003b3; alone or in combination.</p></div></div><div id="Sec7" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec7title">Discussion</h2><p id="__p26" class="p p-first">Binding of IFN-&#x003b1;/&#x003b2; or IFN-&#x003b3; to their specific cell receptors modified the transcriptional and translational environments such that an antiviral state is induced [<a href="#CR26" rid="CR26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739927">26</a>]. However, nearly all the animal viruses evolved mechanisms to antagonize the effect to IFN-induced antiviral state [<a href="#CR27" rid="CR27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845249181">27</a>]. In the case of HSV-1 it was reported that the resistance to IFN&#x003b1;/&#x003b2; is an active process that is dependent on the expression of at least two viral proteins the immediate early protein ICP0 [<a href="#CR28" rid="CR28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845249183">28</a>, <a href="#CR29" rid="CR29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739914">29</a>] and ICP34.5 [<a href="#CR30" rid="CR30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739920">30</a>, <a href="#CR31" rid="CR31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739929">31</a>]. Expression of ICP0 also plays a role in resistance of HSV-1 to IFN-&#x003b3;[<a href="#CR32" rid="CR32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845249184">32</a>]. Thus explaining why IFN&#x003b1;/&#x003b2; or IFN-&#x003b3; alone are weak inhibitors of HSV-1 wild type virus replication. Strikingly, recent studies showed that co-activation of IFN&#x003b1;/&#x003b2; and IFN-&#x003b3; receptors renders cells highly resistant to HSV-1 replication [<a href="#CR20" rid="CR20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739933">20</a>]. This finding is turning to be a general phenomenon since a synergistic antiviral effect of the combination of IFN-&#x003b1; and IFN- &#x003b3; was also demonstrated for other members of <em>Herpesviridae</em> [<a href="#CR20" rid="CR20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739943">20</a>, <a href="#CR23" rid="CR23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739948">23</a>, <a href="#CR33" rid="CR33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739934">33</a>] and a variety of RNA viruses like SARS [<a href="#CR34" rid="CR34" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_848007754">34</a>], Lassa virus [<a href="#CR35" rid="CR35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739925">35</a>] and HCV [<a href="#CR25" rid="CR25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739937">25</a>].</p><p id="__p27">Considering this background the current investigation was undertaken to determine if IFN combination inhibited in a synergistic manner HSV-2 replication in Vero cells, and if so to determine if the presence of the plant derived antiviral compound CDM could affect the antiviral state induced by IFN-&#x003b1; or IFN-&#x003b3; or their combination.</p><p id="__p28">As expected, the results shown in Table <a href="/pmc/articles/PMC1525181/table/Tab1/" target="table" class="fig-table-link figpopup" rid-figpopup="Tab1" rid-ob="ob-Tab1" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">Table1,</span></span><span>1</span></a>, Figure <a href="/pmc/articles/PMC1525181/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure1a</span></span><span>1a</span></a> and Figure <a href="/pmc/articles/PMC1525181/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure2b,</span></span><span>2b</span></a>, clearly demonstrated that HSV-2 plaque formation, viral replication and the onset of viral CPE in Vero cells are synergistically inhibited by interferon combination. Whereas, individual cytokines were weak inducers of the antiviral response, independently of the concentration tried was 100 or 200 IU (Table <a href="/pmc/articles/PMC1525181/table/Tab1/" target="table" class="fig-table-link figpopup" rid-figpopup="Tab1" rid-ob="ob-Tab1" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">(Table1).</span></span><span>1</span></a>). Importantly, there is no evidence that the two cytokines, individually or collectively, were harmful to uninfected or HSV-2 infected cells at the concentration used (Figure <a href="/pmc/articles/PMC1525181/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure2a</span></span><span>2a</span></a> and <a href="/pmc/articles/PMC1525181/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -1.5em;">and2b).</span></span><span>2b</span></a>). To the contrary, the cells remained viable after cytokine exposure for 48 h after the induction period as assessed by MTT exclusion colorimetric method and remained able to proliferate (Figure <a href="/pmc/articles/PMC1525181/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure2a)</span></span><span>2a</span></a>) indicating that virus inhibition was the consequence of a blockade in virus replication and no to host cells death. The validity of these findings was provided by the inclusion of HSV-1 KOS and HSV-1 F strains in the experiments as controls. Results depicted in Table <a href="/pmc/articles/PMC1525181/table/Tab1/" target="table" class="fig-table-link figpopup" rid-figpopup="Tab1" rid-ob="ob-Tab1" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">Table1,</span></span><span>1</span></a>, Figures <a href="/pmc/articles/PMC1525181/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">Figures1c</span></span><span>1c</span></a> and <a href="/pmc/articles/PMC1525181/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -1.5em;">and1g</span></span><span>1g</span></a> (KOS), 1d and 1 h (F) showed a synergistic effect of IFN combination on HSV-1 virus replication confirming previous studies [<a href="#CR36" rid="CR36" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739923">36</a>, <a href="#CR20" rid="CR20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739912">20</a>].</p><p id="__p29">The antiviral effect of CDM in infected cells is due to alterations in cellular processes. Working with VSV as a model system it was demonstrated that CDM exerted its antiviral action on the endocytic and exocytic pathway of VSV by pre- or post-treatment [<a href="#CR37" rid="CR37" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739930">37</a>]. This effect is a consequence that CDM induced cytoplasmic alkalinization of intracellular endosomes. The refractory state to virus infection reached a maximum after 2 h of pre-treatment and is fully maintained up to 12 h later, however even at 24 h the cells still remain partially resistant to virus infection. Since acidification of vacuolar compartments plays an important role in a variety of cellular processes we wondered where the presence of CDM could inhibit the antiviral state induced by interferon treatment.</p><p id="__p30">The results presented in Figure <a href="/pmc/articles/PMC1525181/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure2a</span></span><span>2a</span></a> showed that a concentration of 50 &#x003bc;g/ml of CDM alone or in combination with interferon did not affect uninfected cell viability. Moreover, the presence of CDM, either alone or in combination, for 48 h (Figures <a href="/pmc/articles/PMC1525181/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -4em;">(Figures2b</span></span><span>2b</span></a> and <a href="/pmc/articles/PMC1525181/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -1.5em;">and2c)</span></span><span>2c</span></a>) contributes to protect cells from virus CPE. So, the results obtained were not perturbed by compounds cytopathicity.</p><p id="__p31">To test the antiviral action of IFN we used a standard procedure comprising a period of 16 h cell treatment (induction of the antiviral state) previous to virus infection. IFN was then removed during virus adsorption and after that re-added up to virus harvest. The presence of CDM for 2 h before induction, during the 16 h induction period, only for 24 h after infection or during the complete IFN treatment period did not affect IFN action. On the contrary, in the presence of CDM, an enhanced effect of the antiviral action of each interferon alone or in combination (see Figure <a href="/pmc/articles/PMC1525181/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure3)</span></span><span>3</span></a>) was observed indicating that alteration of cellular processes occurring in cells after exposure to CDM [<a href="#CR37" rid="CR37" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739950">37</a>] did not interfere with the establishment of a refractory stage to HSV-2 infection in cells treated with IFN. It is remarkable that the sensitivity of HSV-2 to CDM increased steadily in accordance with time of cell treatment. Thus, after 2 h pretreatment with CDM virus titer was 2 fold reduced (Figure <a href="/pmc/articles/PMC1525181/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure3a)</span></span><span>3a</span></a>) but if pretreatment was extended to 16 h, virus reduction increased 10 times (Figure <a href="/pmc/articles/PMC1525181/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure3b).</span></span><span>3b</span></a>). In accordance with previous results obtained with meliacine [<a href="#CR5" rid="CR5" class=" bibr popnode">5</a>], addition of CDM to cells after HSV-2 infection caused a strong inhibition of virus titer in the order of 100 fold (Figure <a href="/pmc/articles/PMC1525181/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure3c).</span></span><span>3c</span></a>). Unexpectedly, when CDM was present for 16 h before infection and for 24 h afterwards, virus yield was reduced 20.000 times (Figure <a href="/pmc/articles/PMC1525181/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure3d).</span></span><span>3d</span></a>). This high antiviral activity of CDM <em>per se</em> complicated the interpretation of the results obtained in the presence of IFN (Figure <a href="/pmc/articles/PMC1525181/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure3d),</span></span><span>3d</span></a>), which in comparison reduced the amount of virus even in combination less than 2 logs. To overcome this inconvenience, we performed an experiment with lower concentrations of CDM added after virus infection and lasted to virus harvest, in combination with 100 IU/ml of IFN-&#x003b1; or IFN-&#x003b3;. A clear additive effect of CDM with IFN-&#x003b1; or CDM plus IFN-&#x003b3; at all concentrations tested was observed (Figure <a href="/pmc/articles/PMC1525181/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure4</span></span><span>4</span></a>).</p><p id="__p32" class="p p-last">Thus, the results reported here indicated that the presence of CDM did not alter the biological activity of IFN-&#x003b1; or IFN-&#x003b3; or their combination. As a result we can envision that the administration of CDM <em>in vivo</em> could not affect the production of IFNs, which are so important mediators on the innate resistance to HSV-2 infection [<a href="#CR19" rid="CR19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739918">19</a>].</p></div><div id="Sec8" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec8title">Conclusion</h2><p id="__p33" class="p p-first-last">We have shown here that IFN-&#x003b1;, together with IFN-&#x003b3; synergistically inhibits the replication of HSV-2 <em>in vitro</em> like it was also demonstrated for HSV-1 and others DNA and RNA viruses. On the other hand, we have shown too that CDM display a high antiviral activity against HSV-2 without interfering with the biological activity of IFN. We hypothesize that <em>in vivo</em> administration of CDM could not affect the antiviral activity of interferons to inhibit HSV-2 replication in the mice genital tract.</p></div><div id="Sec9" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec9title">Methods</h2><div id="Sec10" class="sec sec-first"><h3 id="Sec10title">Cells and viruses</h3><p id="__p34" class="p p-first">Vero cells were grown in Eagle\'s minimum essential medium supplemented with 5% inactivated calf serum (MEM 5%) and gentamycin (50 &#x003bc;g/ml) at 37&#x000b0;C in 5% CO<sub>2</sub> and maintained after monolayer formation in MEM supplemented with 1.5% inactivated calf serum (MEM 1.5%).</p><p id="__p35" class="p p-last">Wild type HSV-1 KOS strain was a gift from Dr Erik De Clercq (Rega Institute, Leuven, Belgium). HSV-1 strain F and HSV-2 strains MS and G were obtained from American Type Culture Collection and propagated in Vero cells</p></div><div id="Sec11" class="sec"><h3 id="Sec11title">Interferons</h3><p id="__p36" class="p p-first-last">Recombinant human Interferon.alpha-2 b (Sidus, Buenos Aires, Argentina) and Interferon-gamma 1B (Boehringer Ingelheim, Ingelheim, Germany) were added to cultures 16 h before infection, replaced after HSV infection and maintained until supernatant harvest. In all experiments 100 IU/ml of each interferon were used unless stated otherwise.</p></div><div id="Sec12" class="sec"><h3 id="Sec12title">Antiviral compound</h3><p id="__p37" class="p p-first-last">CDM (1-cinnamoyl-3,11-dihydroxymeliacarpin) was purified in our laboratory from the leaves of <em>M.azedarach</em> L, as described by Alch&#x000e9; <em>et al</em>. [<a href="#CR22" rid="CR22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845249185">22</a>]. Solubilized in MEM 1.5% to a final concentration of 1 mg/ml and stored at -70&#x000b0;C. CDM was used at a concentration of 50 &#x003bc;g/ml (75 &#x003bc;M).</p></div><div id="Sec13" class="sec"><h3 id="Sec13title">Viral plaque reduction assays</h3><p id="__p38" class="p p-first-last">For plaque reduction assay Vero cells were seeded in 24-well plates at a density of 10<sup>5</sup> cells per well, and 12 h later 100 IU/ml of IFN-&#x003b1; or IFN-&#x003b3; or both IFN-&#x003b1; and IFN-&#x003b3; (100 IU/ml of each) were added to the culture medium. Vero cells were inoculated with HSV-2 (strains MS and G) or HSV-1 (strains KOS and F) 16 h later, and after adsorption the medium was replaced with complete MEM containing 1.5% methylcellulose and the same IFNs used in the pretreatment. Plaques were counted two days later.</p></div><div id="Sec14" class="sec"><h3 id="Sec14title">Viral replication assays</h3><p id="__p39" class="p p-first">For virus replication assays, Vero cells were seeded in 24-well plates at a density of 10<sup>5</sup> cells per well, and 12 h later cultures were treated with vehicle, 100 IU/ml of IFN-&#x003b1; and/or 100 IU/ml of IFN-&#x003b3;. After 16 h of IFN treatment, cell monolayers were inoculated with HSV-2 (strains MS and G) or HSV-1 (strains KOS and F) at a multiplicity of infection (MOI) of 1 PFU per cell. After 1 h adsorption, the inoculum was removed and fresh IFN-containing culture medium was returned to each well. Twenty-four, 48 or 72 h p.i., titers of infectious virus in cell supernatants were determined by serial dilution plaque assay on Vero cells.</p><p id="__p40" class="p p-last">To test the effect of CDM on IFN antiviral action we performed different experimental schedule. Vero cells were treated with CDM as follows: <em>i)</em> for 2 h prior to interferon induction and then removed, <em>ii</em>) added simultaneously with IFN and remained only for 16 h before infection, <em>iii</em>) added after virus infection and remained to virus harvested, <em>iiii</em>) added with IFN 16 h before infection, re-added after infection and remained to virus harvested.</p></div><div id="Sec15" class="sec"><h3 id="Sec15title">Enumeration of viable cells</h3><p id="__p41" class="p p-first-last">Vero cells were established at a density of 2 &#x000d7; 10<sup>4</sup> cells/well in 96-well plates and 12 h later fresh culture medium or medium containing 50 &#x003bc;g/ml of CDM or 100 IU/ml of IFN-&#x003b1; or IFN-&#x003b3; or both IFN-&#x003b1; and IFN-&#x003b3; (100 IU/ml of each) alone or in combination with 50 &#x003bc;g/ml of CDM were added to the culture medium. Vero cells were inoculated with HSV-2 MS and HSV-1 KOS 16 h later, and after virus adsorption the medium was replaced with fresh culture medium containing the same IFN concentrations used in the pretreatment. At 0, 12, 24, 36 and 48 h p.i. cell morphology was observed by light microscope and cell viability was determined as described previously [<a href="#CR38" rid="CR38" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844739913">38</a>] using the cleavage of tetrazolium salt MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] (Sigma) by the mitochondrial enzyme succinate dehydrogenase to give a blue product (formazan). The absorbance of each well was measured on an Eurogenetics MPR-A 4i microplate reader, using a test wavelength of 570 nm and a reference wavelength of 630 nm. The number of surviving cells was determined by interpolation in a standard calibration curve correlating optical density values and number of viable cells determined by counting with a haemocytometer.</p></div><div id="Sec16" class="sec sec-last"><h3 id="Sec16title">Statistics</h3><p id="__p42" class="p p-first-last">Data are presented as the means &#x000b1; standard error of the means (sem). Data from IFN-treated groups were compared to vehicle-treated groups and significant differences were determined by one-way analysis of variance (ANOVA) followed by Turkey\'s post hoc <em>t</em> test (GraphPad Prism<sup>&#x000a9;</sup> Home, San Diego, CA).</p></div></div><div id="idm140416958010400" class="tsec sec"><h2 class="head no_bottom_margin" id="idm140416958010400title">Acknowledgements</h2><div class="sec"><p id="__p52">This work was supported by a grant from the University of Buenos Aires (UBA X-046). The authors would like to thank Dr. Laura E. Alch&#x000e9; for kindly supplying the antiviral compound 1-cinnamoyl-3,11-dihydroxymeliacarpin (CDM).</p></div></div><div id="App1" class="tsec sec headless whole_rhythm"><!--/article/back/app-group/app/--><div id="Sec17" class="sec sec-first"><h3 id="Sec17title">Authors&#x02019; original submitted files for images</h3><p id="__p43" class="p p-first-last">Below are the links to the authors&#x02019; original submitted files for images.<span class="sup-box" id="MOESM1"><a href="/pmc/articles/PMC1525181/bin/12985_2006_152_MOESM1_ESM.pdf" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 1</a><sup>(55K, pdf)</sup></span><span class="sup-box" id="MOESM2"><a href="/pmc/articles/PMC1525181/bin/12985_2006_152_MOESM2_ESM.pdf" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 2</a><sup>(48K, pdf)</sup></span><span class="sup-box" id="MOESM3"><a href="/pmc/articles/PMC1525181/bin/12985_2006_152_MOESM3_ESM.pdf" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 3</a><sup>(106K, pdf)</sup></span><span class="sup-box" id="MOESM4"><a href="/pmc/articles/PMC1525181/bin/12985_2006_152_MOESM4_ESM.pdf" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 4</a><sup>(35K, pdf)</sup></span></p></div></div><div id="idm140416954244272" class="tsec sec"><h2 class="head no_bottom_margin" id="idm140416954244272title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="idm140416954244144"><p id="__p48" class="p p-first"><strong>Competing interests</strong></p><p id="__p49" class="p p-last">The author(s) declare that they have no competing interests.</p></p><p class="fn sec" id="idm140416954242816"><p id="__p50" class="p p-first"><strong>Authors\' contributions</strong></p><p id="__p51" class="p p-last">EP participated in the experimental design, performed all experiments and drafted the manuscript. CEC conceived and design of the study, and drafted the manuscript. Both authors read and approved the final manuscript.</p></p></div></div><div id="idm140416959295824aff-info" class="tsec sec"><h2 class="head no_bottom_margin" id="idm140416959295824aff-infotitle">Contributor Information</h2><p><span class="fm-affl">Erina Petrera, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ra.abu.necf.bq@arertepe" class="oemail">ra.abu.necf.bq@arertepe</a></span>.</p><p><span class="fm-affl">Celia E Coto, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ra.abu.necf.bq@otocoriv" class="oemail">ra.abu.necf.bq@otocoriv</a></span>.</p></div><div id="Bib1" class="tsec sec"><h2 class="head no_bottom_margin" id="Bib1title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="CR1">1. <span class="element-citation">Waltz MA, Price RW, Hayashi K, Katz BJ, Notkins AL. Effect of immunization on acute and latent infections of vagino-uterine tissue with herpes simplex virus type 1 and 2. <span><span class="ref-journal">J Infect Dis. </span>1977;<span class="ref-vol">135</span>:744\xe2\x80\x93752. doi: 10.1093/infdis/135.5.744.</span> [<a href="/pubmed/192810" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1093%2Finfdis%2F135.5.744" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Infect+Dis&amp;title=Effect+of+immunization+on+acute+and+latent+infections+of+vagino-uterine+tissue+with+herpes+simplex+virus+type+1+and+2&amp;author=MA+Waltz&amp;author=RW+Price&amp;author=K+Hayashi&amp;author=BJ+Katz&amp;author=AL+Notkins&amp;volume=135&amp;publication_year=1977&amp;pages=744-752&amp;pmid=192810&amp;doi=10.1093/infdis/135.5.744&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR2">2. <span class="element-citation">Richards JT, Kern ER, Overall JC, Glasgow LA. Differences in neurovirulence among isolates of herpes simplex virus types 1 and 2 in mice using four routs of infection. <span><span class="ref-journal">J Infect Dis. </span>1981;<span class="ref-vol">144</span>:464\xe2\x80\x93471. doi: 10.1093/infdis/144.5.464.</span> [<a href="/pubmed/6273475" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1093%2Finfdis%2F144.5.464" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Infect+Dis&amp;title=Differences+in+neurovirulence+among+isolates+of+herpes+simplex+virus+types+1+and+2+in+mice+using+four+routs+of+infection&amp;author=JT+Richards&amp;author=ER+Kern&amp;author=JC+Overall&amp;author=LA+Glasgow&amp;volume=144&amp;publication_year=1981&amp;pages=464-471&amp;pmid=6273475&amp;doi=10.1093/infdis/144.5.464&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR3">3. <span class="element-citation">Smee DF, Martin JC, Verheyden JPH, Matthews TR. Anti-herpesvirus activity of the acyclic nuclioside 9-(1,3-dihydroxy-2-propoxymethyl) guanine. <span><span class="ref-journal">Antimicrobial Agents and Chemotherapy. </span>1983;<span class="ref-vol">23</span>:676\xe2\x80\x93682. doi: 10.1128/AAC.23.5.676.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC184786/">PMC free article</a>]</span> [<a href="/pubmed/6307132" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1128%2FAAC.23.5.676" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Antimicrobial+Agents+and+Chemotherapy&amp;title=Anti-herpesvirus+activity+of+the+acyclic+nuclioside+9-(1,3-dihydroxy-2-propoxymethyl)+guanine&amp;author=DF+Smee&amp;author=JC+Martin&amp;author=JPH+Verheyden&amp;author=TR+Matthews&amp;volume=23&amp;publication_year=1983&amp;pages=676-682&amp;pmid=6307132&amp;doi=10.1128/AAC.23.5.676&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR4">4. <span class="element-citation">Whaley KJ, Barratt RA, Zeitlin L, Hoen TE, Cone RA. Nonoxynol-9-protects mice against vaginal transmission of genital herpes infections. <span><span class="ref-journal">J Infect Dis. </span>1993;<span class="ref-vol">168</span>:1009\xe2\x80\x931111. doi: 10.1093/infdis/168.4.1009.</span> [<a href="/pubmed/8397261" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1093%2Finfdis%2F168.4.1009" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Infect+Dis&amp;title=Nonoxynol-9-protects+mice+against+vaginal+transmission+of+genital+herpes+infections&amp;author=KJ+Whaley&amp;author=RA+Barratt&amp;author=L+Zeitlin&amp;author=TE+Hoen&amp;author=RA+Cone&amp;volume=168&amp;publication_year=1993&amp;pages=1009-1111&amp;pmid=8397261&amp;doi=10.1093/infdis/168.4.1009&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR5">5. <span class="element-citation">Andrei G, Couto AS, de Lederkremer RM, Coto CE. Purification and partial characterization of an antiviral active peptide from Melia azedarach L. <span><span class="ref-journal">Antivir Chem Chemother. </span>1994;<span class="ref-vol">5</span>:105\xe2\x80\x93110. doi: 10.1177/095632029400500207.</span> [<a href="//dx.doi.org/10.1177%2F095632029400500207" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Antivir+Chem+Chemother&amp;title=Purification+and+partial+characterization+of+an+antiviral+active+peptide+from+Melia+azedarach+L&amp;author=G+Andrei&amp;author=AS+Couto&amp;author=RM+de+Lederkremer&amp;author=CE+Coto&amp;volume=5&amp;publication_year=1994&amp;pages=105-110&amp;doi=10.1177/095632029400500207&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR6">6. <span class="element-citation">Barquero AA, Alch&#x000e9; LE, Coto CE. Antiviral activity of meliacine on the replication of a thymidine kinase-deficient mutant of herpes simplex virus type 1 alone and in combination with acyclovir. <span><span class="ref-journal">Int J Antimicrob Agents. </span>1997;<span class="ref-vol">9</span>:49. doi: 10.1016/S0924-8579(97)00023-X.</span> [<a href="/pubmed/18611819" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0924-8579(97)00023-X" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Antimicrob+Agents&amp;title=Antiviral+activity+of+meliacine+on+the+replication+of+a+thymidine+kinase-deficient+mutant+of+herpes+simplex+virus+type+1+alone+and+in+combination+with+acyclovir&amp;author=AA+Barquero&amp;author=LE+Alch&#x000e9;&amp;author=CE+Coto&amp;volume=9&amp;publication_year=1997&amp;pages=49&amp;pmid=18611819&amp;doi=10.1016/S0924-8579(97)00023-X&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR7">7. <span class="element-citation">Alch&#x000e9; LE, Barquero AA, San Juan NA, Coto CE. An antiviral principle present in a purified fraction from Melia azedarach L leaves aqous extracts restreing herpes simplex virus type 1 propagation. <span><span class="ref-journal">Phytother Res. </span>2002;<span class="ref-vol">16</span>:348\xe2\x80\x93352. doi: 10.1002/ptr.895.</span> [<a href="/pubmed/12112291" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1002%2Fptr.895" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Phytother+Res&amp;title=An+antiviral+principle+present+in+a+purified+fraction+from+Melia+azedarach+L+leaves+aqous+extracts+restreing+herpes+simplex+virus+type+1+propagation&amp;author=LE+Alch&#x000e9;&amp;author=AA+Barquero&amp;author=NA+San+Juan&amp;author=CE+Coto&amp;volume=16&amp;publication_year=2002&amp;pages=348-352&amp;pmid=12112291&amp;doi=10.1002/ptr.895&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR8">8. <span class="element-citation">Alch&#x000e9; LE, Berra A, Beloso MJ, Coto CE. Treatment with meliacine, a plant derived antiviral, prevents the development of herpetic stromal keratitis in mice. <span><span class="ref-journal">J Med Virol. </span>2000;<span class="ref-vol">61</span>:474\xe2\x80\x9380. doi: 10.1002/1096-9071(200008)61:4&#x0003c;474::AID-JMV10&#x0003e;3.0.CO;2-K.</span> [<a href="/pubmed/10897066" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1002%2F1096-9071(200008)61%3A4%3C474%3A%3AAID-JMV10%3E3.0.CO%3B2-K" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Med+Virol&amp;title=Treatment+with+meliacine,+a+plant+derived+antiviral,+prevents+the+development+of+herpetic+stromal+keratitis+in+mice&amp;author=LE+Alch&#x000e9;&amp;author=A+Berra&amp;author=MJ+Beloso&amp;author=CE+Coto&amp;volume=61&amp;publication_year=2000&amp;pages=474-80&amp;pmid=10897066&amp;doi=10.1002/1096-9071(200008)61:4&#x0003c;474::AID-JMV10&#x0003e;3.0.CO;2-K&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR9">9. <span class="element-citation">Pifarr&#x000e9; MP, Berra A, Coto CE, Alch&#x000e9; LE. Therapeutic action of meliacine, a plant-derived antiviral, on HSV-induced ocular disease in mice. <span><span class="ref-journal">Exp Eye Res. </span>2002;<span class="ref-vol">75</span>:327\xe2\x80\x9334. doi: 10.1016/S0014-4835(02)92027-0.</span> [<a href="/pubmed/12384095" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0014-4835(02)92027-0" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Exp+Eye+Res&amp;title=Therapeutic+action+of+meliacine,+a+plant-derived+antiviral,+on+HSV-induced+ocular+disease+in+mice&amp;author=MP+Pifarr&#x000e9;&amp;author=A+Berra&amp;author=CE+Coto&amp;author=LE+Alch&#x000e9;&amp;volume=75&amp;publication_year=2002&amp;pages=327-34&amp;pmid=12384095&amp;doi=10.1016/S0014-4835(02)92027-0&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR10">10. <span class="element-citation">Petrera E, Coto CE. Efectos de la administraci&#x000f3;n in vivo del antiviral meliacina sobre el curso de la infecci&#x000f3;n herp&#x000e9;tica genital murina [abstract] <span><span class="ref-journal">Medicina. </span>2004;<span class="ref-vol">64</span>(Suppl II):337.</span> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Medicina&amp;title=Efectos+de+la+administraci&#x000f3;n+in+vivo+del+antiviral+meliacina+sobre+el+curso+de+la+infecci&#x000f3;n+herp&#x000e9;tica+genital+murina+[abstract]&amp;author=E+Petrera&amp;author=CE+Coto&amp;volume=64&amp;issue=Suppl+II&amp;publication_year=2004&amp;pages=337&amp;pmid=15338977&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR11">11. <span class="element-citation">Courr&#x000e8;ges MC, Benencia F, Coto CE, Massouh EJ, Coulombi&#x000e9; FC. In vitro antiphagocytic effect of Melia azedarach leaf extracts on mouse peritoneal exudate cells. <span><span class="ref-journal">J Ethnopharmacol. </span>1994;<span class="ref-vol">43</span>:135\xe2\x80\x9340. doi: 10.1016/0378-8741(94)90010-8.</span> [<a href="/pubmed/7967653" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2F0378-8741(94)90010-8" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Ethnopharmacol&amp;title=In+vitro+antiphagocytic+effect+of+Melia+azedarach+leaf+extracts+on+mouse+peritoneal+exudate+cells&amp;author=MC+Courr&#x000e8;ges&amp;author=F+Benencia&amp;author=CE+Coto&amp;author=EJ+Massouh&amp;author=FC+Coulombi&#x000e9;&amp;volume=43&amp;publication_year=1994&amp;pages=135-40&amp;pmid=7967653&amp;doi=10.1016/0378-8741(94)90010-8&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR12">12. <span class="element-citation">Courr&#x000e8;ges MC, Benencia F, Coulombi&#x000e9; FC, Coto CE. In vitro and in vivo activities of Melia azedarach L. aqueous leaf extracts on murine lymphocytes. <span><span class="ref-journal">Phytomedicine. </span>1998;<span class="ref-vol">5</span>:47\xe2\x80\x9353. doi: 10.1016/S0944-7113(98)80059-7.</span> [<a href="/pubmed/23195699" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0944-7113(98)80059-7" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Phytomedicine&amp;title=In+vitro+and+in+vivo+activities+of+Melia+azedarach+L.+aqueous+leaf+extracts+on+murine+lymphocytes&amp;author=MC+Courr&#x000e8;ges&amp;author=F+Benencia&amp;author=FC+Coulombi&#x000e9;&amp;author=CE+Coto&amp;volume=5&amp;publication_year=1998&amp;pages=47-53&amp;pmid=23195699&amp;doi=10.1016/S0944-7113(98)80059-7&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR13">13. <span class="element-citation">Petrera E, Coto CE. Effect of meliacine, a plant derived antiviral, on tumor necrosis factor alpha. <span><span class="ref-journal">Fitoterapia. </span>2003;<span class="ref-vol">74</span>:77\xe2\x80\x9383. doi: 10.1016/S0367-326X(02)00294-0.</span> [<a href="/pubmed/12628398" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0367-326X(02)00294-0" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Fitoterapia&amp;title=Effect+of+meliacine,+a+plant+derived+antiviral,+on+tumor+necrosis+factor+alpha&amp;author=E+Petrera&amp;author=CE+Coto&amp;volume=74&amp;publication_year=2003&amp;pages=77-83&amp;pmid=12628398&amp;doi=10.1016/S0367-326X(02)00294-0&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR14">14. <span class="element-citation">Ellerman-Eriksen S. Autocrine secretion of interferon-alpha/beta and tumor necrosis factor-alpha synergistically activates macrophages after infection with herpes simples virus type 2. <span><span class="ref-journal">J Gen Virol. </span>1993;<span class="ref-vol">74</span>:2191\xe2\x80\x932199. doi: 10.1099/0022-1317-74-10-2191.</span> [<a href="/pubmed/8409942" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1099%2F0022-1317-74-10-2191" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Gen+Virol&amp;title=Autocrine+secretion+of+interferon-alpha/beta+and+tumor+necrosis+factor-alpha+synergistically+activates+macrophages+after+infection+with+herpes+simples+virus+type+2&amp;author=S+Ellerman-Eriksen&amp;volume=74&amp;publication_year=1993&amp;pages=2191-2199&amp;pmid=8409942&amp;doi=10.1099/0022-1317-74-10-2191&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR15">15. <span class="element-citation">Bohem U, Klamp T, Groot M, Howard JC. Cellular response to interferon-&#x003b3; <span><span class="ref-journal">Annu Rev Immunol. </span>1997;<span class="ref-vol">15</span>:749\xe2\x80\x93795. doi: 10.1146/annurev.immunol.15.1.749.</span> [<a href="/pubmed/9143706" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1146%2Fannurev.immunol.15.1.749" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Annu+Rev+Immunol&amp;title=Cellular+response+to+interferon-&#x003b3;&amp;author=U+Bohem&amp;author=T+Klamp&amp;author=M+Groot&amp;author=JC+Howard&amp;volume=15&amp;publication_year=1997&amp;pages=749-795&amp;pmid=9143706&amp;doi=10.1146/annurev.immunol.15.1.749&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR16">16. <span class="element-citation">Paludan SR, Ellermann-Eriksen S, Mogensen SC. NF-kappaB activation is responsible for the synergistic effect of herpes simplex virus type 2 infection on interferon-gamma-induced nitric oxide production. <span><span class="ref-journal">J Gen Virol. </span>1998;<span class="ref-vol">79</span>:2785\xe2\x80\x932793. doi: 10.1099/0022-1317-79-11-2785.</span> [<a href="/pubmed/9820155" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1099%2F0022-1317-79-11-2785" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Gen+Virol&amp;title=NF-kappaB+activation+is+responsible+for+the+synergistic+effect+of+herpes+simplex+virus+type+2+infection+on+interferon-gamma-induced+nitric+oxide+production&amp;author=SR+Paludan&amp;author=S+Ellermann-Eriksen&amp;author=SC+Mogensen&amp;volume=79&amp;publication_year=1998&amp;pages=2785-2793&amp;pmid=9820155&amp;doi=10.1099/0022-1317-79-11-2785&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR17">17. <span class="element-citation">Malmgaard L, Paludan SR, Mogensen SC, Ellermann-Eriksen S. Herpes simplex virus type 2 induces interleukin-12 in macrophages through a mechanism involving NF-&#x003ba;B. <span><span class="ref-journal">J Gen Virol. </span>2000;<span class="ref-vol">81</span>:3011\xe2\x80\x933020. doi: 10.1099/0022-1317-81-12-3011.</span> [<a href="/pubmed/11086132" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1099%2F0022-1317-81-12-3011" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Gen+Virol&amp;title=Herpes+simplex+virus+type+2+induces+interleukin-12+in+macrophages+through+a+mechanism+involving+NF-&#x003ba;B&amp;author=L+Malmgaard&amp;author=SR+Paludan&amp;author=SC+Mogensen&amp;author=S+Ellermann-Eriksen&amp;volume=81&amp;publication_year=2000&amp;pages=3011-3020&amp;pmid=11086132&amp;doi=10.1099/0022-1317-81-12-3011&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR18">18. <span class="element-citation">Vollstedt S, Arnold S, Schwerdel C, Franchini M, Alber Gottfried, Di Santo JP, Ackermann M, Suter M. Interplay between alpha/beta and gamma interferons with B, T and natural killer cells in the defense against herpes simplex virus type 1. <span><span class="ref-journal">J of Virol. </span>2004;<span class="ref-vol">78</span>:3846\xe2\x80\x933850. doi: 10.1128/JVI.78.8.3846-3850.2004.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC374284/">PMC free article</a>]</span> [<a href="/pubmed/15047800" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1128%2FJVI.78.8.3846-3850.2004" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+of+Virol&amp;title=Interplay+between+alpha/beta+and+gamma+interferons+with+B,+T+and+natural+killer+cells+in+the+defense+against+herpes+simplex+virus+type+1&amp;author=S+Vollstedt&amp;author=S+Arnold&amp;author=C+Schwerdel&amp;author=M+Franchini&amp;author=Gottfried+Alber&amp;volume=78&amp;publication_year=2004&amp;pages=3846-3850&amp;pmid=15047800&amp;doi=10.1128/JVI.78.8.3846-3850.2004&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR19">19. <span class="element-citation">Malmgaard L, Paludan SR. Interferon (IFN)-&#x003b1;/&#x003b2;, interleukin (IL)-12 and IL-18 coordinately induce production of IFN-&#x003b3; during infection with herpes simplex virus type 2. <span><span class="ref-journal">J Gen Virol. </span>2003;<span class="ref-vol">84</span>:2497\xe2\x80\x932500. doi: 10.1099/vir.0.19251-0.</span> [<a href="/pubmed/12917471" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1099%2Fvir.0.19251-0" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Gen+Virol&amp;title=Interferon+(IFN)-&#x003b1;/&#x003b2;,+interleukin+(IL)-12+and+IL-18+coordinately+induce+production+of+IFN-&#x003b3;+during+infection+with+herpes+simplex+virus+type+2&amp;author=L+Malmgaard&amp;author=SR+Paludan&amp;volume=84&amp;publication_year=2003&amp;pages=2497-2500&amp;pmid=12917471&amp;doi=10.1099/vir.0.19251-0&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR20">20. <span class="element-citation">Sainz B, Jr, Halford W. Alpha/beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1. <span><span class="ref-journal">J of Virol. </span>2002;<span class="ref-vol">76</span>:11541\xe2\x80\x9311550. doi: 10.1128/JVI.76.22.11541-11550.2002.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC136787/">PMC free article</a>]</span> [<a href="/pubmed/12388715" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1128%2FJVI.76.22.11541-11550.2002" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+of+Virol&amp;title=Alpha/beta+interferon+and+gamma+interferon+synergize+to+inhibit+the+replication+of+herpes+simplex+virus+type+1&amp;author=B+Sainz&amp;author=W+Halford&amp;volume=76&amp;publication_year=2002&amp;pages=11541-11550&amp;pmid=12388715&amp;doi=10.1128/JVI.76.22.11541-11550.2002&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR21">21. <span class="element-citation">Mikloska Z, Cunningham AL. Alpha and gamma interferons inhibit herpes simplez virus type I infection and spread in epidermal cells after axonal tranmission. <span><span class="ref-journal">J Virol. </span>2001;<span class="ref-vol">75</span>:11821\xe2\x80\x9311826. doi: 10.1128/JVI.75.23.11821-11826.2001.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC114768/">PMC free article</a>]</span> [<a href="/pubmed/11689663" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1128%2FJVI.75.23.11821-11826.2001" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Alpha+and+gamma+interferons+inhibit+herpes+simplez+virus+type+I+infection+and+spread+in+epidermal+cells+after+axonal+tranmission&amp;author=Z+Mikloska&amp;author=AL+Cunningham&amp;volume=75&amp;publication_year=2001&amp;pages=11821-11826&amp;pmid=11689663&amp;doi=10.1128/JVI.75.23.11821-11826.2001&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR22">22. <span class="element-citation">Alch&#x000e9; LE, Ferek GA, Meo M, Coto CE, Meier MS. An antiviral meliacarpin from leaves of Melia azedarach L. <span><span class="ref-journal">Z Naturforsch. </span>2003;<span class="ref-vol">58</span>:215\xe2\x80\x93219.</span> [<a href="/pubmed/12710731" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Z+Naturforsch&amp;title=An+antiviral+meliacarpin+from+leaves+of+Melia+azedarach+L&amp;author=LE+Alch&#x000e9;&amp;author=GA+Ferek&amp;author=M+Meo&amp;author=CE+Coto&amp;author=MS+Meier&amp;volume=58&amp;publication_year=2003&amp;pages=215-219&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR23">23. <span class="element-citation">Pierce AT, De Salvo J, Foster TP, Kosinski A, S&#x000e9;ller SK, Halford WP. Beta interferon and gamma interferon synergize to block DNA and virion synthesis in herpes simplex virus-infected cells. <span><span class="ref-journal">J Gen Virol. </span>2005;<span class="ref-vol">86</span>:2421\xe2\x80\x932432. doi: 10.1099/vir.0.80979-0.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1366490/">PMC free article</a>]</span> [<a href="/pubmed/16099899" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1099%2Fvir.0.80979-0" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Gen+Virol&amp;title=Beta+interferon+and+gamma+interferon+synergize+to+block+DNA+and+virion+synthesis+in+herpes+simplex+virus-infected+cells&amp;author=AT+Pierce&amp;author=J+De+Salvo&amp;author=TP+Foster&amp;author=A+Kosinski&amp;author=SK+S&#x000e9;ller&amp;volume=86&amp;publication_year=2005&amp;pages=2421-2432&amp;pmid=16099899&amp;doi=10.1099/vir.0.80979-0&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR24">24. <span class="element-citation">Desloges N, Rahaus M, Wolff MH. Role of protein kinase PKR in the inhibition of varicella-zoster virus replication by beta interferon and gamma interferon. <span><span class="ref-journal">J Gen Virol. </span>2005;<span class="ref-vol">86</span>:1\xe2\x80\x936. doi: 10.1099/vir.0.80466-0.</span> [<a href="/pubmed/15604425" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1099%2Fvir.0.80466-0" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Gen+Virol&amp;title=Role+of+protein+kinase+PKR+in+the+inhibition+of+varicella-zoster+virus+replication+by+beta+interferon+and+gamma+interferon&amp;author=N+Desloges&amp;author=M+Rahaus&amp;author=MH+Wolff&amp;volume=86&amp;publication_year=2005&amp;pages=1-6&amp;pmid=15604425&amp;doi=10.1099/vir.0.80466-0&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR25">25. <span class="element-citation">Sainz B, Jr, LaMarca HL, Garry RF, Morris C. Synergistic inhibition of human cytomegalovirus replication by interferon-alpha/beta and interferon-gamma. <span><span class="ref-journal">Virol J. </span>2005;<span class="ref-vol">2</span>:14. doi: 10.1186/1743-422X-2-14.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC554982/">PMC free article</a>]</span> [<a href="/pubmed/15727684" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1186%2F1743-422X-2-14" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Virol+J&amp;title=Synergistic+inhibition+of+human+cytomegalovirus+replication+by+interferon-alpha/beta+and+interferon-gamma&amp;author=B+Sainz&amp;author=HL+LaMarca&amp;author=RF+Garry&amp;author=C+Morris&amp;volume=2&amp;publication_year=2005&amp;pages=14&amp;pmid=15727684&amp;doi=10.1186/1743-422X-2-14&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR26">26. <span class="element-citation">Samuel CE. Antiviral action of interferons. <span><span class="ref-journal">Clinical Microbiology Reviews. </span>2001;<span class="ref-vol">14</span>:778\xe2\x80\x93809. doi: 10.1128/CMR.14.4.778-809.2001.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC89003/">PMC free article</a>]</span> [<a href="/pubmed/11585785" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1128%2FCMR.14.4.778-809.2001" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clinical+Microbiology+Reviews&amp;title=Antiviral+action+of+interferons&amp;author=CE+Samuel&amp;volume=14&amp;publication_year=2001&amp;pages=778-809&amp;pmid=11585785&amp;doi=10.1128/CMR.14.4.778-809.2001&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR27">27. <span class="element-citation">Tan SL, Katze MG. HSV.com: maneuvering the internetworks of viral neuropathogenesis and evasion of the host defense. <span><span class="ref-journal">Proc Natl Acad Sci U S. </span>2000;<span class="ref-vol">97</span>:5684\xe2\x80\x935686. doi: 10.1073/pnas.97.11.5684.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC33987/">PMC free article</a>]</span> [<a href="/pubmed/10823927" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1073%2Fpnas.97.11.5684" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S&amp;title=HSV.com:+maneuvering+the+internetworks+of+viral+neuropathogenesis+and+evasion+of+the+host+defense&amp;author=SL+Tan&amp;author=MG+Katze&amp;volume=97&amp;publication_year=2000&amp;pages=5684-5686&amp;doi=10.1073/pnas.97.11.5684&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR28">28. <span class="element-citation">Leib DA, Harrison TE, Laslo KM, Machalek MA, Moorman NJ, Virgin HW. Interferons regulate the phenotype of wild-type and mutant herpes simplex virus in vivo. <span><span class="ref-journal">J Exp Medicine. </span>1999;<span class="ref-vol">189</span>:663\xe2\x80\x93672. doi: 10.1084/jem.189.4.663.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2192939/">PMC free article</a>]</span> [<a href="/pubmed/9989981" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1084%2Fjem.189.4.663" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Exp+Medicine&amp;title=Interferons+regulate+the+phenotype+of+wild-type+and+mutant+herpes+simplex+virus+in+vivo&amp;author=DA+Leib&amp;author=TE+Harrison&amp;author=KM+Laslo&amp;author=MA+Machalek&amp;author=NJ+Moorman&amp;volume=189&amp;publication_year=1999&amp;pages=663-672&amp;doi=10.1084/jem.189.4.663&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR29">29. <span class="element-citation">Mossman KL, Sherburne R, Lavery C, Duncan J, Smiley JR. Evidence that herpes simplex virus VP16 is required for viral egress downstream of the initial envelopment event. <span><span class="ref-journal">J Virol. </span>2000;<span class="ref-vol">74</span>:6287\xe2\x80\x9399. doi: 10.1128/JVI.74.14.6287-6299.2000.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC112134/">PMC free article</a>]</span> [<a href="/pubmed/10864638" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1128%2FJVI.74.14.6287-6299.2000" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Evidence+that+herpes+simplex+virus+VP16+is+required+for+viral+egress+downstream+of+the+initial+envelopment+event&amp;author=KL+Mossman&amp;author=R+Sherburne&amp;author=C+Lavery&amp;author=J+Duncan&amp;author=JR+Smiley&amp;volume=74&amp;publication_year=2000&amp;pages=6287-99&amp;pmid=10864638&amp;doi=10.1128/JVI.74.14.6287-6299.2000&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR30">30. <span class="element-citation">Cassady KA, Gross M, Roizman B. The second-site mutation in the herpes simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha. <span><span class="ref-journal">J Virol. </span>1998;<span class="ref-vol">72</span>:7005\xe2\x80\x9311.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC109920/">PMC free article</a>]</span> [<a href="/pubmed/9696792" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=The+second-site+mutation+in+the+herpes+simplex+virus+recombinants+lacking+the+gamma134.5+genes+precludes+shutoff+of+protein+synthesis+by+blocking+the+phosphorylation+of+eIF-2alpha&amp;author=KA+Cassady&amp;author=M+Gross&amp;author=B+Roizman&amp;volume=72&amp;publication_year=1998&amp;pages=7005-11&amp;pmid=9696792&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR31">31. <span class="element-citation">Leib DA, Machalek MA, Williams BR, Silverman RH, Virgin HW. Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2000;<span class="ref-vol">97</span>:6097\xe2\x80\x93101. doi: 10.1073/pnas.100415697.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC18564/">PMC free article</a>]</span> [<a href="/pubmed/10801979" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1073%2Fpnas.100415697" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S+A&amp;title=Specific+phenotypic+restoration+of+an+attenuated+virus+by+knockout+of+a+host+resistance+gene&amp;author=DA+Leib&amp;author=MA+Machalek&amp;author=BR+Williams&amp;author=RH+Silverman&amp;author=HW+Virgin&amp;volume=97&amp;publication_year=2000&amp;pages=6097-101&amp;pmid=10801979&amp;doi=10.1073/pnas.100415697&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR32">32. <span class="element-citation">H&#x000e4;rle P, Sainz B, Carr DJ, Halford WP. The immediate-early protein, ICP0, is essential for the resistance of herpes simplex virus to interferon alpha/beta. <span><span class="ref-journal">Virol. </span>2002;<span class="ref-vol">293</span>:295\xe2\x80\x93304. doi: 10.1006/viro.2001.1280.</span> [<a href="/pubmed/11886249" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1006%2Fviro.2001.1280" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Virol&amp;title=The+immediate-early+protein,+ICP0,+is+essential+for+the+resistance+of+herpes+simplex+virus+to+interferon+alpha/beta&amp;author=P+H&#x000e4;rle&amp;author=B+Sainz&amp;author=DJ+Carr&amp;author=WP+Halford&amp;volume=293&amp;publication_year=2002&amp;pages=295-304&amp;doi=10.1006/viro.2001.1280&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR33">33. <span class="element-citation">Halford WP, Halford KJ, Pierce AT. Mathematical analysis demonstrates that interferons-beta and -gamma interact in a multiplicative manner to disrupt herpes simplex virus replication. <span><span class="ref-journal">J Theor Biol. </span>2005;<span class="ref-vol">234</span>:439\xe2\x80\x9354. doi: 10.1016/j.jtbi.2004.12.007.</span> [<a href="/pubmed/15784277" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.jtbi.2004.12.007" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Theor+Biol&amp;title=Mathematical+analysis+demonstrates+that+interferons-beta+and+-gamma+interact+in+a+multiplicative+manner+to+disrupt+herpes+simplex+virus+replication&amp;author=WP+Halford&amp;author=KJ+Halford&amp;author=AT+Pierce&amp;volume=234&amp;publication_year=2005&amp;pages=439-54&amp;pmid=15784277&amp;doi=10.1016/j.jtbi.2004.12.007&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR34">34. <span class="element-citation">Sainz B, Jr, Mossel EC, Peters CJ, Garry RF. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) <span><span class="ref-journal">Virol. </span>2004;<span class="ref-vol">329</span>:11\xe2\x80\x9317. doi: 10.1016/j.virol.2004.08.011.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7111895/">PMC free article</a>]</span> [<a href="/pubmed/15476870" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.virol.2004.08.011" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Virol&amp;title=Interferon-beta+and+interferon-gamma+synergistically+inhibit+the+replication+of+severe+acute+respiratory+syndrome-associated+coronavirus+(SARS-CoV)&amp;author=B+Sainz&amp;author=EC+Mossel&amp;author=CJ+Peters&amp;author=RF+Garry&amp;volume=329&amp;publication_year=2004&amp;pages=11-17&amp;doi=10.1016/j.virol.2004.08.011&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR35">35. <span class="element-citation">Asper M, Sternsdorf T, Hass M, Drosten C, Rhode A, Schmitz H, G&#x000fc;nther S. Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus. <span><span class="ref-journal">J Virol. </span>2004;<span class="ref-vol">78</span>:3162\xe2\x80\x933169. doi: 10.1128/JVI.78.6.3162-3169.2004.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC353741/">PMC free article</a>]</span> [<a href="/pubmed/14990737" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1128%2FJVI.78.6.3162-3169.2004" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Inhibition+of+different+Lassa+virus+strains+by+alpha+and+gamma+interferons+and+comparison+with+a+less+pathogenic+arenavirus&amp;author=M+Asper&amp;author=T+Sternsdorf&amp;author=M+Hass&amp;author=C+Drosten&amp;author=A+Rhode&amp;volume=78&amp;publication_year=2004&amp;pages=3162-3169&amp;pmid=14990737&amp;doi=10.1128/JVI.78.6.3162-3169.2004&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR36">36. <span class="element-citation">Balish MJ, Abrams ME, Pumfery AM, Brandt CR. Enhanced inhibition of herpes simplex virus type 1 growth in human corneal fibroblasts by combinations of interferon-alpha and -gamma. <span><span class="ref-journal">J Infect Dis. </span>1992;<span class="ref-vol">166</span>:1401\xe2\x80\x933. doi: 10.1093/infdis/166.6.1401.</span> [<a href="/pubmed/1331251" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1093%2Finfdis%2F166.6.1401" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Infect+Dis&amp;title=Enhanced+inhibition+of+herpes+simplex+virus+type+1+growth+in+human+corneal+fibroblasts+by+combinations+of+interferon-alpha+and+-gamma&amp;author=MJ+Balish&amp;author=ME+Abrams&amp;author=AM+Pumfery&amp;author=CR+Brandt&amp;volume=166&amp;publication_year=1992&amp;pages=1401-3&amp;pmid=1331251&amp;doi=10.1093/infdis/166.6.1401&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR37">37. <span class="element-citation">Barquero AA, Alch&#x000e9; LE, Coto CE. Block of vesicular stomatitis virus endocytic and exocytic pathways by 1-cinnamoyl-3,11-dihydroxymeliacarpin, a tetranortriterpenoid of natural origin. <span><span class="ref-journal">J Gen Virol. </span>2004;<span class="ref-vol">85</span>:483\xe2\x80\x9393. doi: 10.1099/vir.0.19343-0.</span> [<a href="/pubmed/14769906" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1099%2Fvir.0.19343-0" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Gen+Virol&amp;title=Block+of+vesicular+stomatitis+virus+endocytic+and+exocytic+pathways+by+1-cinnamoyl-3,11-dihydroxymeliacarpin,+a+tetranortriterpenoid+of+natural+origin&amp;author=AA+Barquero&amp;author=LE+Alch&#x000e9;&amp;author=CE+Coto&amp;volume=85&amp;publication_year=2004&amp;pages=483-93&amp;pmid=14769906&amp;doi=10.1099/vir.0.19343-0&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR38">38. <span class="element-citation">Petrera E, Joselevich M, Ghini A, Burton G, Coto CE. Antiherpes virus activities of new 6&#x02013;19 carbon-bridged steroids and some synthetic precursors. <span><span class="ref-journal">Antivir Chem Chemother. </span>2003;<span class="ref-vol">14</span>:243\xe2\x80\x938. doi: 10.1177/095632020301400503.</span> [<a href="/pubmed/14694987" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1177%2F095632020301400503" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Antivir+Chem+Chemother&amp;title=Antiherpes+virus+activities+of+new+6&#x02013;19+carbon-bridged+steroids+and+some+synthetic+precursors&amp;author=E+Petrera&amp;author=M+Joselevich&amp;author=A+Ghini&amp;author=G+Burton&amp;author=CE+Coto&amp;volume=14&amp;publication_year=2003&amp;pages=243-8&amp;pmid=14694987&amp;doi=10.1177/095632020301400503&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=1525181&amp;issue-id=354810&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--></div>\n            \n            \n        \n            \n        </div>\n        <!-- Book content -->\n    </div>\n    \n    <div id="rightcolumn" class="four_col col last">\n        <!-- Custom content above discovery portlets -->\n        <div class="col6">\n            \n        </div>\n        \n        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC1525181/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC1525181/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC1525181/pdf/12985_2006_Article_152.pdf">PDF (339K)</a></li> | <li><a href="#" data-citationid="PMC1525181" class="citationexporter ctxp">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1525181%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook" />\n                             Facebook\n                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1525181%2F&amp;text=The%20synergistic%20effect%20of%20IFN-%CE%B1%20and%20IFN-%CE%B3%20against%20HSV-2%20replication%20in%20Vero%20cells%20is%20not%20interfered%20by%20the%20plant%20antiviral%201-cinnamoyl-3%2C%2011-dihydroxymeliacarpin"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter" />\n                             Twitter\n                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1525181%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus" />\n                             Google+\n                        </a></li></ul></div>\n        \n        <div id="ajax-portlets" data-pmid="16772029" data-aiid="7095765" data-aid="1525181" data-iid="354810" data-domainid="3814" data-domain="phenaturepg" data-accid="PMC1525181" data-md5="29b2a0c015a70b5430b440d070237301"></div>\n                \n        <!-- Custom content below discovery portlets -->\n        <div class="col7">\n            \n        </div>\n    </div>\n</div>\n\n<!-- Custom content after all -->\n<div class="col8">\n    \n</div>\n<div class="col9">\n    \n</div>\n\n<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>\n<script>\n    (function($){\n        $(\'.skiplink\').each(function(i, item){\n            var href = $($(item).attr(\'href\'));\n            href.attr(\'tabindex\', \'-1\').addClass(\'skiptarget\'); // ensure the target can receive focus\n            $(item).on(\'click\', function(event){\n                event.preventDefault();\n                $.scrollTo(href, 0, {\n                    onAfter: function(){\n                        href.focus();\n                    }\n                });\n            });\n        });\n    })(jQuery);\n</script>\n\n\n\n<div id="body-link-poppers"></div>\n                        </div>\n                        <div class="bottom">\n                            \n                            <div id="NCBIFooter_dynamic">\n    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>\n    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2020-04-17T09:17:11-04:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=ptpmc102&amp;ncbi_phid=8A1B67CAE999B5B10000000008A208A1&amp;ncbi_session=8A1B67CAE99AC561_2210SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1525181%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>\n    \n</div>\n\n                            <div class="footer" id="footer">\n    \n    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>\n    <div id="external-disclaimer" class="offscreen_noflow">\n        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.\n    </div>    \n    <div id="ncbifooter" class="contact_info">      \n        <div id="footer-contents-right">\n            <div id="nlm_thumb_logo">\n                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>\n            </div>\n            <div id="nih_thumb_logo">\n                <a href="https://www.nih.gov" title="NIH">NIH</a>\n            </div>\n            <div id="hhs_thumb_logo">\n                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>\n            </div>\n            <div id="usagov_thumb_logo">\n                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>\n            </div>         \n        </div>\n        \n        <div id="footer-contents-left">\n            <p class="address vcard">\n                <span class="url">\n                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for\n                        Biotechnology Information</a>,\n                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>\n                <span class="adr">\n                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>\n                    <span class="region">MD</span>, <span class="postal-code">20894</span>\n                    <span class="country-name">USA</span>\n                </span>\n            </p>\n            \n            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>\n        </div>\n    </div>\n    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    \n    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>\n</div>\n                        </div>\n                    </div>\n                    <!--/.page-->\n                </div>\n                <!--/.wrap-->\n            </div><!-- /.twelve_col -->\n        </div>\n        <!-- /.grid -->\n\n        <span class="PAFAppResources"></span>\n        \n        <!-- BESelector tab -->\n        \n        \n        \n        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=phenaturepg&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC1525181/&amp;ncbi_app=pmc" /></noscript>\n        \n        \n        <!-- usually for JS scripts at page bottom -->\n        <!--<component id="PageFixtures" label="styles"></component>-->\n    \n\n<!-- 8A1B67CAE99AC561_2210SID /projects/PMC/PMCViewer@4.46 ptpmc102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->\n\n<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script></body>\n</html>'